Savient Announces Named Patient Programme for KRYSTEXXA in the European Union for Patients with Refractory Chronic Gout

Savient Pharmaceuticals, Inc. SVNT today announced that KRYSTEXXA®(pegloticase) is now available in the European Union to healthcare professionals and their patients suffering from refractory chronic gout through a Named Patient Programme, which is sponsored by its wholly-owned subsidiary, Savient Pharma Ireland Limited, and managed by Idis Limited. RCG is a difficult-to-treat form of gout and currently there are no other available therapies approved in the European Union for the treatment of RCG. KRYSTEXXA is currently available in the U.S. and is the only U.S. Food and Drug Administration approved treatment for RCG.